Richard van der Mast
Overview
Explore the profile of Richard van der Mast including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
43
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Mogeda C, van Gool M, van der Mast R, Nijland R, Keasberry Z, van de Bovekamp L, et al.
Sci Rep
. 2024 Oct;
14(1):25540.
PMID: 39462090
Intrathecal synthesis of immunoglobulins (Igs) is a key hallmark of multiple sclerosis (MS). B cells are known to accumulate in the leptomeninges of MS patients and associate with pathology in...
2.
van Delft M, Aleyd E, van der Mast R, de Jong N, Boon L, Simons P, et al.
Front Immunol
. 2023 Apr;
14:1118539.
PMID: 37081893
Introduction: Immunoglobulin A (IgA) is mostly considered as a non-inflammatory regulator at mucosal areas. However, previous work of our group showed that IgA can also be involved in disease pathology,...
3.
Bos A, van Gool M, Breedveld A, van der Mast R, Marsman C, Bouma G, et al.
Int J Mol Sci
. 2022 Oct;
23(19).
PMID: 36232432
Patients with inflammatory bowel disease (IBD) produce enhanced immunoglobulin A (IgA) against the microbiota compared to healthy individuals, which has been correlated with disease severity. Since IgA complexes can potently...
4.
Gruijs M, Ganzevles S, Stigter-van Walsum M, van der Mast R, van Ostaijen-Ten Dam M, Tuk C, et al.
Int J Mol Sci
. 2021 Oct;
22(20).
PMID: 34681717
The immunosuppressive character of head and neck cancers may explain the relatively low response rates to antibody therapy targeting a tumor antigen, such as cetuximab, and anti-PD-1 checkpoint inhibition. Immunostimulatory...
5.
van Harten A, Buijze M, van der Mast R, Rooimans M, Martens-de Kemp S, Bachas C, et al.
Oncogenesis
. 2019 Jun;
8(7):38.
PMID: 31209198
Head and neck squamous cell carcinomas (HNSCCs) coincide with poor survival rates. The lack of driver oncogenes complicates the development of targeted treatments for HNSCC. Here, we follow-up on two...